A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder

PURPOSE: Vibegron, a novel, potent β3 agonist, has been approved for clinical use in overactive bladder (OAB) treatment in Japan and the Unites States. We performed a bridging study to investigate the efficacy and safety of a daily 50-mg vibegron (code name JLP-2002) dose in Korean patients with OAB...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jung Hyun, Jeong, Seong Jin, Kim, Sun-Ouck, Oh, Cheol Young, Chung, Kyung Jin, Shin, Dong Gil, Kim, Tae Hyo, Kwon, Joonbeom, Shin, Ju-Hyun, Bae, Woong Jin, Lee, Kyu-Sung, Choo, Myung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Continence Society 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325944/
https://www.ncbi.nlm.nih.gov/pubmed/37401021
http://dx.doi.org/10.5213/inj.2346022.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325944/
https://www.ncbi.nlm.nih.gov/pubmed/37401021
http://dx.doi.org/10.5213/inj.2346022.011

Ejemplares similares